Clinical Pharmacokinetics

, Volume 39, Issue 1, pp 49–75

Drug Interactions with Cisapride

Clinical Implications
  • Elizabeth Landrum Michalets
  • Charlene Rhinehart Williams
Review Articles Drug Interactions

Abstract

Cisapride, a prokinetic agent, has been used for the treatment of a number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and children. Since 1993, 341 cases of ventricular arrhythmias, including 80 deaths, have been reported to the US Food and Drug Administration. Marketing of the drug has now been discontinued in the US; however, it is still available under a limited-access protocol. Knowledge of the risk factors for cisapride-associated arrhythmias will be essential for its continued use in those patients who meet the eligibility criteria. This review summarises the published literature on the pharmacokinetic and pharmacodynamic interactions of cisapride with concomitantly administered drugs, providing clinicians with practical recommendations for avoiding these potentially fatal events.

Pharmacokinetic interactions with cisapride involve inhibition of cytochrome P450 (CYP) 3A4, the primary mode of elimination of cisapride, thereby increasing plasma concentrations of the drug. The macrolide antibacterials clarithromycin, erythromycin and troleandomycin are inhibitors of CYP3A4 and should not be used in conjunction with cisapride. Azithromycin is an alternative. Similarly, azole antifungal agents such as fluconazole, itraconazole and ketoconazole are CYP3A4 inhibitors and their concomitant use with cisapride should be avoided.

Of the antidepressants nefazodone and fluvoxamine should be avoided with cisapride. Data with fluoxetine is controversial, we favour the avoidance of its use. Citalopram, paroxetine and sertraline are alternatives.

The HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir inhibit CYP3A4. Clinical experience with cisapride is lacking but avoidance with all protease inhibitors is recommended, although saquinavir is thought to have clinically insignificant effects on CYP3A4. Delavirdine is also a CYP3A4 inhibitor and should be avoided with cisapride.

We also recommend avoiding coadministration of cisapride with amiodarone, cimetidine (alternatives are famotidine, nizatidine, ranitidine or one of the proton pump inhibitors), diltiazem and verapamil (the dihydropyridine calcium antagonists are alternatives), grapefruit juice, isoniazid, metronidazole, quinine, quinupristin/dalfopristin and zileuton (montelukast is an alternative).

Pharmacodynamic interactions with cisapride involve drugs that have the potential to have additive effects on the QT interval. We do not recommend use of cisapride with class Ia and III antiarrhythmic drugs or with adenosine, bepridil, cyclobenzaprine, droperidol, haloperidol, nifedipine (immediate release), phenothiazine antipsychotics, tricyclic and tetracyclic antidepressants or vasopressin. Vigilance is advised if anthracyclines, cotrimoxazole (trimethoprim-sulfamethoxazole), enflurane, halothane, isoflurane, pentamidine or probucol are used with cisapride. In addition, uncorrected electrolyte disturbances induced by diuretics may increase the risk of torsade de pointes. Patients receiving cisapride should be promptly treated for electrolyte disturbances.

References

  1. 1.
    Wiseman RL, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47 (1): 116–52.PubMedCrossRefGoogle Scholar
  2. 2.
    McCallum RW, Prakash C, Campoli-Richards DM, et al. Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Reynolds JC. Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. Am J Health-Syst Pharm 1996; 53 Suppl. 3: S5–12.PubMedGoogle Scholar
  4. 4.
    Briejer MR, Akkermans LMA, Schuurres JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631–51.PubMedGoogle Scholar
  5. 5.
    Vandenpias Y, Belli D, Benatar A, et al. The role of cisapride in the treatment of pediatric gastroesophagel reflux. J Pediatr Gastroenterol Nutr 1999; 28: 518–28.CrossRefGoogle Scholar
  6. 6.
    DeVault KR, Castell D. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995; 155: 2165–73.PubMedCrossRefGoogle Scholar
  7. 7.
    Janssen Pharmaceutica Inc. Limited-access program announced in United States to ensure appropriate use of Propulsid® (cisapride): product no longer to be promoted in United States [media release, 2 pages]. 2000 Mar 23. Available from: URL: http://www.us.janssen.com/news/cur-rent/propuls lim acc.html [accessed 2000 May 29].Google Scholar
  8. 8.
    Food and Drug Administration. Janssen Pharmaceutica stops marketing cisapride in the US [talk paper, 1 page]. 2000 Mar 23. Available from: http://www.fda.gov/bbs/topics/AN-SWERS/ANS01007.html [accessed 2000 May 30].Google Scholar
  9. 9.
    Meuldermans W, Van Peer A, Hendricks J, et al. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988; 16: 403–9.PubMedGoogle Scholar
  10. 10.
    Corinaldesi R, Stanghellini V, Tosetti C, et al. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993; 44: 429–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Mohammad S, Zhou Z, Gonng Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: 2534–8.Google Scholar
  12. 12.
    Michalets EL. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998; 18 (1): 84–112.PubMedGoogle Scholar
  13. 13.
    Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619–24.PubMedGoogle Scholar
  14. 14.
    Rendie S, Di Carlo F. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29: 413–580.CrossRefGoogle Scholar
  15. 15.
    Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220–39.PubMedCrossRefGoogle Scholar
  16. 16.
    Guengerich FP. Polymorphism of cytochrome P450 in humans. Trends Pharmacol Sci 1989; 10 (3): 107–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Faber TS, Zehender M, Just H. Drug-induced torsade de pointes: incidence, management and prevention. Drug Saf 1994; 11 (6): 463–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Lazzara R. Antiarrhythmic drugs and torsade de points. Eur Heart J 1993; 14 Suppl. H: 88–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Lehmann MH, Hardy S, Archibald D, et al. Sex differences in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94: 2535–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Keren A, Tzivoni D, Gavish D. Etiology, warning signs and therapy of torsade de pointes: a study of 10 patients. Circulation 1981; 64: 1167–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Roden DM. Arrhythmogenic potential of class HI antiarrhythmic agents: comparison with Class I agents. In: Singh BN, editor. Control of cardiac arrhythmias by lengthening repolarization. Mt Kisco: Futura Publishing Co., 1988: 559–77.Google Scholar
  22. 22.
    Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: the long-short initiating sequence and clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2: 806–17.PubMedCrossRefGoogle Scholar
  23. 23.
    Bateman DN. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30: 205–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Francois I, Nutte ND. Nonulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987; 41 (6): 891–8.Google Scholar
  25. 25.
    Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305: 748–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Bedu A, Lupoglazoff JM, Faure C. Cisapride high dosage and long QT interval [letter]. J Pediatr 1997; 130: 164.PubMedGoogle Scholar
  27. 27.
    Gray VS. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998; 32: 648–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Sakkarje MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997; 30 (3): 437–9.CrossRefGoogle Scholar
  29. 29.
    Hill, SL, Evangelista JK, Pizzi AM, et al. Proarrhythmias associated with cisapride in children. Pediatrics 1998; 101 (6): 1053–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Bran S, Murray WA, Hirsch IB, et al. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 756–8.CrossRefGoogle Scholar
  31. 31.
    Thomas AR, Chan LN, Bauman JL, et al. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998; 18 (2): 381–5.PubMedGoogle Scholar
  32. 32.
    Khongphatthanayothin A, Lane J, Thomas D, et al. Effects of cisapride on QT interval in children. J Pediatr 1998; 133: 51–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Lewin MB, Bryant RM, Fenrich AL, et al. Cisapride-induced long QT interval. J Pediatr 1996; 128: 279–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Pettignano R, Chambliss CR, Darsey E, et al. Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Crit Care Med 1996; 24: 1268–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Valdes L, Champel V, Olivier C, et al. Syncope with long QT interval in a 39 day-old infant treated with cisapride [in French]. Arch Pediatr 1997; 4 (6): 535–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Vitola J, Vukanovic J, Roden DM. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 1998; 9: 1109–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacotherapy 1999; 33: 22–6.CrossRefGoogle Scholar
  38. 38.
    van Haarst AD, van’t Klooster GAE, van Gerven KMA, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64: 542–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Jenkins IR, Gibson J. Cisapride, erythromycin and arrhythmia. Anaesth Intens Care 1996; 24 (6): 728.Google Scholar
  40. 40.
    Bernardini S, Semama DS, Heut F, et al. Effects of cisapride on QTc interval in neonates. Arch Dis Child Fetal Neonatal Ed 1997; 77 (3): F241–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Ahmad SR, Wolfe SM. Cisapride and torsades de pointes [letter]. Lancet 1995; 345: 508.CrossRefGoogle Scholar
  42. 42.
    Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290–1.PubMedCrossRefGoogle Scholar
  43. 43.
    Tan HL, Hou CJY, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de points. Ann Intern Med 1995; 122: 701–14.PubMedGoogle Scholar
  44. 44.
    Inman W, Kubota K. Tachycardia during cisapride treatment [abstract]. BMJ 1992; 305: 1019.PubMedCrossRefGoogle Scholar
  45. 45.
    Tack JT, Janssens F. A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Drug Saf 1995; 12 (6): 384–92.PubMedCrossRefGoogle Scholar
  46. 46.
    Wager E, Tooley PJH, Pearce GL, et al. A comparison of two cohort studies evaluating the safety of cisapride: prescription-event monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52: 87–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Janssen Pharmaceutica, Inc. Propulsid (cisapride) package insert. Titusville (NJ): Janssen Pharmaceutica, Inc., 2000.Google Scholar
  48. 48.
    Humphrey PPA, Bunce KT. Tachycardia during cisapride treatment [letter]. BMJ 1992; 304: 1019.CrossRefGoogle Scholar
  49. 49.
    Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Carlsson L, Amos G, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997; 282: 220–7.PubMedGoogle Scholar
  51. 51.
    Puisieux FL, Adamantidis MM, Dumotier BM, et al. Cisaprideinduced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 1377–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Periti P, Mazzei T, Mini E, et al. Pharmacokinetic interactions of macrolides. Clin Pharmacokinet 1992; 23: 106–31.PubMedCrossRefGoogle Scholar
  53. 53.
    Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18 (5): 595–606.PubMedGoogle Scholar
  54. 54.
    Jurima-Romet M, Crawford K, Cyr T, et al. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22 (6): 849–57.PubMedGoogle Scholar
  55. 55.
    Gascon MP, Dayer P. Comparative effects of macrolide antibiotics on liver monoxygenases. Clin Pharmacol Ther 1991; 49: 158.Google Scholar
  56. 56.
    Aoki, FY, Yatscoff R, Jeffrey J, et al. Effects of erythromycin on cyclosporin A kinetics in renal transplant patients [abstract]. Clin Pharmacol Ther 1987; 41: 221.Google Scholar
  57. 57.
    Jensen CWB, Flechner SM, Van Buren CT, et al. Exacerbation of cyclosporin toxicity by concomitant administration of erythromycin. Transplantation 1987; 43: 263–70.PubMedCrossRefGoogle Scholar
  58. 58.
    Honig P, Wortham DC, Zamani K, et al. Effect of erythromycin, clarithromycin and azithromycin on the pharmacokinetic s of terfenadine [abstract]. Clin Pharmacol Ther 1993; 53: 161.CrossRefGoogle Scholar
  59. 59.
    Phillips JP, Antal EJ, Smith RB. A pharmacokinetic interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986; 6: 297–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Warot D, Bergougnan L, Lamiable D, et al. Troleandomycintriazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987; 32: 389–93.PubMedCrossRefGoogle Scholar
  61. 61.
    Gillum JG, Israel DS, Polk R. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25 (6): 450–82.PubMedCrossRefGoogle Scholar
  62. 62.
    Harris S, Hilligoss DM, Colangelo PM, et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995; 58: 310–15.PubMedCrossRefGoogle Scholar
  63. 63.
    Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996.Google Scholar
  64. 64.
    Oberg K, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995; 15: 687–92.PubMedGoogle Scholar
  65. 65.
    Lai D, Brown G, MacDonald I. Clarithromycin-induced prolonged QT syndrome. Can J Hosp Pharm 1996; 49: 33–5.Google Scholar
  66. 66.
    Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995; 29: 906–17.PubMedGoogle Scholar
  67. 67.
    Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Anal 1991; 72: 137–44.CrossRefGoogle Scholar
  68. 68.
    Stratmann HG, Kennedy HL. Torsade de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987; 113 (6): 1470–82.PubMedCrossRefGoogle Scholar
  69. 69.
    Roden DM, Thompson KA, Hoffman BF, et al. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 1986; 8: 73A–78A.PubMedCrossRefGoogle Scholar
  70. 70.
    Bauman JL, Bauernfeind RA, Hoff JV, et al. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J 1984; 107: 425–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Strasberg B, Schlarvosky S, Erdberg A, et al. Procainamide-in-duced polymorphous ventricular tachycardia. Am J Cardiol 1981; 47: 1309–14.PubMedCrossRefGoogle Scholar
  72. 72.
    Riccioni N, Castiglioni M, Bartolomei C. Disopyramide-in-duced QT prolongation and ventricular tachy arrhythmias. Am Heart J 1983; 105 (5): 870–1.PubMedCrossRefGoogle Scholar
  73. 73.
    Selzer A, Wray AH. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17–26.PubMedCrossRefGoogle Scholar
  74. 74.
    Olshanksy B, Martins J, Hunt S. N-acetyl procainamide causing torsade de pointes. Am J Cardiol 1982; 50: 1439–40.CrossRefGoogle Scholar
  75. 75.
    Herre JM, Thompson JA. Polymorphic ventricular tachycardia and ventricular fibrillation due to N-acetyl procainamide. Am J Cardiol 1985; 55: 227–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Stratmann HG, Walter KE, Kennedy HL. Torsade de pointes associated with elevated N-acetylprocainamide levels. Am Heart J 1985; 109:375–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Lo KS, Gantz KB, Stetson PL, et al. Disopyramide-induced ventricular tachycardia. Arch Intern Med 1980; 140: 413–4.PubMedCrossRefGoogle Scholar
  78. 78.
    Tzivoni D, Keren A, Stern S, et al. Disopyramide-induced torsade de pointes. Arch Intern Med 1981; 141: 946–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Neuvovnen PJ, Elonen E, Tanskanen A, et al Sotalol and prolonged Q-Tc interval [letter]. Lancet 1981; II: 426.CrossRefGoogle Scholar
  80. 80.
    Hohnloser SH, Arendts W, Quart B. Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF [abstract]. Pacing Clin Electrophysiol 1992; 15: 551.CrossRefGoogle Scholar
  81. 81.
    Kuck KH, Roewer N, Bleifeld W. Sotalol-induced torsade de pointes. Am Heart J 1984; 107: 179–80.PubMedCrossRefGoogle Scholar
  82. 82.
    McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalemia, syncope, and torsade de pointes. Br Heart J 1984; 51: 157–62.PubMedCrossRefGoogle Scholar
  83. 83.
    Howard PA. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 1999; 33: 38–47.PubMedCrossRefGoogle Scholar
  84. 84.
    Kowey PR, Vanderlugt JT. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996; 78(8a Suppl.): 46–52.PubMedCrossRefGoogle Scholar
  85. 85.
    Laganiere S, Davies RF, Carignan G, et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 1996; 60: 255–64.PubMedCrossRefGoogle Scholar
  86. 86.
    Levy RH. Cytochrome P450 isoenzyme and antiepileptic drug interactions. Epilepsia 1995; 36 Suppl. 5: S8–13.PubMedCrossRefGoogle Scholar
  87. 87.
    Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992; 51: 398–407.PubMedCrossRefGoogle Scholar
  88. 88.
    Walker DK, Alabaster CT, Congrave GS, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide: in vitro studies and correlation with in vivo data. Drug Metab Dispos 1996; 24 (4): 447–55.PubMedGoogle Scholar
  89. 89.
    Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55 (3): 256–69.PubMedCrossRefGoogle Scholar
  90. 90.
    Duenas-Laita A, Bary MG, MacMathuna P, et al. Effects of chronic treatment with amiodarone on hepatic demethylation and cytochrome P450. J Pharm Pharmacol 1987; 39 (9): 757–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Bhandari AK, Quock C, Sung RJ. Polymorphous ventricular tachycardia associated with a marked prolongation of the Q-T interval induced by amiodarone. Pacing Clin Electrophysiol 1984; 7: 341–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Mattioni TA, Zheutlin TA, Sarmiento JJ, et al. Amiodarone in patients with previous drug-mediated torsade de pointes. Ann Intern Med 1989; 111 (7): 574–80.PubMedGoogle Scholar
  93. 93.
    Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med 1989; 111 (7): 549–50.PubMedGoogle Scholar
  94. 94.
    Hii JTY, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86; 1376–82.PubMedCrossRefGoogle Scholar
  95. 95.
    Sclarvosky S, Lewin RF, Kracoff O, et al. Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J 1983; 105 (1): 6–12.CrossRefGoogle Scholar
  96. 96.
    Wesley RC, Turnquest P. Torsade de pointe after intravenous adenosine in the presence of prolonged QT syndrome. Am Heart J 1992; 123 (3): 794–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Rubart M, Pressler ML, Pride HP, et al. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993; 88: 1832–44.PubMedCrossRefGoogle Scholar
  98. 98.
    Freedman RA, Anderson KP, Green LS, et al. Effect of erythromycin on ventricular arrhythmias an ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 1987; 59: 168–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Gitler B, Berger LS, Buffa SD. Torsade de pointes induced by erythromycin. Chest 1994; 105: 368–72.PubMedCrossRefGoogle Scholar
  100. 100.
    Nattel S, Ranger S, Talajic M, et al. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990; 89: 235–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture. FASEB J 1992; 6 (2): 752–8.PubMedGoogle Scholar
  102. 102.
    Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996; 31 (3): 198–214.PubMedCrossRefGoogle Scholar
  103. 103.
    Hismanal. FDA Med Bull 1996; 269 (2): 4.Google Scholar
  104. 104.
    Mirghani RA, Hellgren R, Westerberg PA, et al. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther 1999; 66: 454–60.PubMedCrossRefGoogle Scholar
  105. 105.
    Cantelli-Forte G, Paolini M, et al. Effects of metronidazole, asanidazole and azathioprine on cytochrome P450 and various monoxygenase activities in hepatic microsome from control and induced mice. Arch Toxicol 1987; 11 Suppl.: 264–9.Google Scholar
  106. 106.
    Cooke CE, Sklar GE, Nappi JM. Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Ann Pharmacother 1996; 30 (4): 365–6.Google Scholar
  107. 107.
    Spinier SA, Cheng JWM, Kindawall KE, et al. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995; 57: 89–95.CrossRefGoogle Scholar
  108. 108.
    Borcherding SM, Stevens R, Nicholas RA. Quinolones: a practical review of clinical uses, dosing consideration, and drug interactions. J Fam Pract 1996; 42: 69–78.PubMedGoogle Scholar
  109. 109.
    Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfapristin: administration guidelines. J Antimicrob Chemother 1999; 44 Suppl. A: 37–46.PubMedCrossRefGoogle Scholar
  110. 110.
    Ballow C, Chevalier P, Forrest A, et al. Randomized, crossover, phase I study of the interactions between quinupristin/ dalfopristin (Q/D), (RP 59500, Synercid) at steady state and cyclosporine in healthy volunteers [abstract 2313:43]. Twentieth International Congress of Chemotherapy; 1997 Jun 28-Jul 3; Sydney.Google Scholar
  111. 111.
    Lopez JA, Harold JG, Rosenthal MC, et al. QT prolongation and torsade de pontes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 1987; 376–7.Google Scholar
  112. 112.
    Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23–31.CrossRefGoogle Scholar
  113. 113.
    Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311–20.PubMedGoogle Scholar
  114. 114.
    Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf 1997; 17 (6): 390–406.PubMedCrossRefGoogle Scholar
  115. 115.
    DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998; 59 Suppl. 20: 85–93.Google Scholar
  116. 116.
    Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72: 835–47.PubMedCrossRefGoogle Scholar
  117. 117.
    Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Pharmacol 1994; 46: 35–9.Google Scholar
  118. 118.
    Bedford TA, Rowbotham DJ. Cisapride: drug interactions of clinical significance. Drug Saf 1996; 15 (3): 167–75.PubMedCrossRefGoogle Scholar
  119. 119.
    Fritz J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991; 84: 583–4.CrossRefGoogle Scholar
  120. 120.
    Martin DE, Zussman B, Everitt DE, et al. No effect of paroxetine on the cardiac safety and pharmacokinetics of terfenadine [abstract]. J Clin Pharmacol 1996; 36: 849.Google Scholar
  121. 121.
    Martin DE, Zussman BD, Everitt DE, et al. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol 1997; 17 (6): 451–9.PubMedCrossRefGoogle Scholar
  122. 122.
    Rapeport WG, Williams SA, Muirhead DC, et al. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996; 57 Suppl. 1:20–3.PubMedGoogle Scholar
  123. 123.
    Lasher TA, Fleishaker JC, Steenwyk RC, et al. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991; 104: 323–7.PubMedCrossRefGoogle Scholar
  124. 124.
    Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52: 479–86.PubMedCrossRefGoogle Scholar
  125. 125.
    Swims MR Potential terfenadine-fluoxetine interaction. Ann Pharmacother 1993; 27: 1404–5.PubMedGoogle Scholar
  126. 126.
    Marchiando RJ, Cook MD, Jue SG. Probable terfenadine-fluoxetine-associated cardiac toxicity. Ann Pharmacother 1995; 27: 937–8.Google Scholar
  127. 127.
    Wright CE, Lasher-Sisson TA, Steenwyk RC, et al. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992; 12: 103–6.PubMedGoogle Scholar
  128. 128.
    Strouse TB, Fairbanks LA, Skotzko CE, et al. Fluoxetine and cyclosporine in organ transplantation. Psychosomatics 1996; 37: 23–30.PubMedCrossRefGoogle Scholar
  129. 129.
    Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34 (4): 281–302.PubMedCrossRefGoogle Scholar
  130. 130.
    Sommi R, Crismon L, Bowden C. Fluoxetine: a serotonin-specific second generation antidepressant. Pharmacotherapy 1987; 7: 1–15.PubMedGoogle Scholar
  131. 131.
    Bergstrom RF, Goldberg MJ, Cerimele BJ, et al. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 1997; 62: 643–51.PubMedCrossRefGoogle Scholar
  132. 132.
    Zhao Q, Zheng M, Wojcik MA, et al. The effect of multiple doses of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride in healthy volunteers [abstract]. American College of Clinical Pharmacy Annual Meeting; 1999 Oct 24–27; Kansas City, MO.Google Scholar
  133. 133.
    Eli Lilly and Company. Prozac (fluoxetine) package insert. Indianapolis (IN): Eli Lilly and Co., 1997.Google Scholar
  134. 134.
    Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 16 Suppl. 2: 37S–50S.PubMedCrossRefGoogle Scholar
  135. 135.
    Russell JL. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment-refractory depression. J Clin Psychopharmacol 1996; 16 (1): 35–7.PubMedCrossRefGoogle Scholar
  136. 136.
    Kasper S, Praschak-Rieder N, Tauscher J, et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 17 (4): 251–64.PubMedCrossRefGoogle Scholar
  137. 137.
    Owen RJ, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7 Suppl. 1: 24–32.PubMedCrossRefGoogle Scholar
  138. 138.
    Barbhaiya RH, Shukla UA, Kroboth PD, et al. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995; 15: 306–26.PubMedCrossRefGoogle Scholar
  139. 139.
    Solvay Pharmaceuticals. Luvox (fluvoxamine) package insert. Marietta (GA): Solvay Pharmaceuticals, 1998.Google Scholar
  140. 140.
    Bristol Myers Squibb, Co. Serzone (nefazodone) package insert. Princeton (NJ): Bristol Myers Squibb, Co., 1998.Google Scholar
  141. 141.
    Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996; 41 (4): 339–43.PubMedCrossRefGoogle Scholar
  142. 142.
    Fowler HO, McCall D, Chou TC, et al. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976; 37: 223–30.PubMedCrossRefGoogle Scholar
  143. 143.
    Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications. Am Heart J 1982; 103 (3): 401–14.PubMedCrossRefGoogle Scholar
  144. 144.
    Bigger JT, Giardina EGV, Perel JM, et al. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med 1977; 296 (4): 206–9.PubMedCrossRefGoogle Scholar
  145. 145.
    Giardina EGV, Bigger J, Glassman AH, et al. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation 1979; 60(5): 1045–52.PubMedCrossRefGoogle Scholar
  146. 146.
    Herrmann HC, Kaplan LM, Bierer BE. Q-T prolongation and torsade de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983; 51: 904–6.PubMedCrossRefGoogle Scholar
  147. 147.
    Burckhardt D, Raeder E, Muller V, et al. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978; 239: 213–6.PubMedCrossRefGoogle Scholar
  148. 148.
    Back DJ, Tija JE Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32 (5): 624–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36 (9): 783–91.Google Scholar
  150. 150.
    Janssen propulsid concomitant use with nizoral contraindicated. FDC Report — Pink Sheet 1995 Mar 13: 14.Google Scholar
  151. 151.
    Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45 (2): 191–3.PubMedCrossRefGoogle Scholar
  152. 152.
    Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interactions. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269 (12): 1513–8.PubMedCrossRefGoogle Scholar
  153. 153.
    Monohan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90.CrossRefGoogle Scholar
  154. 154.
    Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Interaction of triazolam and ketoconazole [letter]. Lancet 1995; 345: 191.PubMedCrossRefGoogle Scholar
  155. 155.
    Jalava K-M, Olkkola KT, Neuvomen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410–5.PubMedCrossRefGoogle Scholar
  156. 156.
    Honig PK, Worham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53 (6): 630–6.PubMedCrossRefGoogle Scholar
  157. 157.
    Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996; 42 (4): 465–70.PubMedCrossRefGoogle Scholar
  158. 158.
    Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996; 41 (4): 319–23.PubMedCrossRefGoogle Scholar
  159. 159.
    Neuvonen PJ, Varhe A, Olkkola T. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996; 60: 326–31.PubMedCrossRefGoogle Scholar
  160. 160.
    Zeneca Pharmaceuticals. Accolate (zafirlukast) package insert. Wilmington (DE): Zeneca Pharmaceuticals, 1998.Google Scholar
  161. 161.
    NHLBI, National Asthma Education and Prevention Program, Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NIH Publication No. 97–4051. Bethesda (MD): US Department of Health and Human Services, 1997.Google Scholar
  162. 162.
    Granneman GR, Braechman RA, Cavanaugh JH, et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 1995; 29 Suppl. 2: 77–83.PubMedCrossRefGoogle Scholar
  163. 163.
    Lau R. Drug interactions with zileuton. Lancet 1997; 349: 1479–80.PubMedCrossRefGoogle Scholar
  164. 164.
    Marion Merrell Dow. Seldane (terfenadine) package insert. Kansas City (MO): Marion Merrell Dow, 1993.Google Scholar
  165. 165.
    Awni WM, Cavanaugh JH, Leese P. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol 1997; 52 (1): 49–54.PubMedCrossRefGoogle Scholar
  166. 166.
    Abbott Laboratories. Zyflo (Zileuton) package insert. Chicago (IL): Abbott Laboratories, 1997.Google Scholar
  167. 167.
    Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999; 39 (5): 495–500.PubMedGoogle Scholar
  168. 168.
    Malmstrom K, Schwartz J, Reiss TF, et al. Effect of montelukast on single-dose theophylline pharmacokinetics. Am J Ther 1998; 5 (3): 189–95.PubMedCrossRefGoogle Scholar
  169. 169.
    Sharma ND, Rosman HS, Padhi D, et al. Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 239–40.CrossRefGoogle Scholar
  170. 170.
    Wilt JL, Minnema AM, Johnson RF, et al. Torsade de pointes associated with use of intravenous haloperidol. Ann Intern Med 1993; 119:391–4.PubMedGoogle Scholar
  171. 171.
    Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperidol-in-duced torsade de pointes. Chest 1990; 98 (2): 482–4.PubMedCrossRefGoogle Scholar
  172. 172.
    Flugelman MY, Tal A, Pollack S, et al. Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 1985; 46: 290–1.PubMedGoogle Scholar
  173. 173.
    Kemper AJ, Dulap R, Pietro DA. Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol. JAMA 1983; 249 (21): 2931–4.PubMedCrossRefGoogle Scholar
  174. 174.
    Kitayama H, Kiuchi K, Nejima J, et al. Long-term treatment with antipsychotic drugs in convention doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999; 55: 259–62.PubMedCrossRefGoogle Scholar
  175. 175.
    Drici MD, Wang WX, Liu XK, et al. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998; 18 (6): 477–81.PubMedCrossRefGoogle Scholar
  176. 176.
    O’Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother 1999; 33: 1046–50.PubMedCrossRefGoogle Scholar
  177. 177.
    Roche Pharmaceuticals. Fotovase (saquinavir soft gel caps) package insert. Nutley (NJ): Roche Pharmaceuticals, 1998.Google Scholar
  178. 178.
    Agouron Pharmaceuticals. Viracept (nelfinavir) package insert. La Jolla (CA): Agouron Pharmaceuticals, 1997.Google Scholar
  179. 179.
    Abbott Laboratories. Norvir (ritonavir) package insert. North Chicago (IL): Abbott Laboratories, 1999.Google Scholar
  180. 180.
    Merck and Company, Inc. Crixivan (indinavir) package insert. West Point (PA): Merck and Co., 1998.Google Scholar
  181. 181.
    Amprenavir: a new HIV protease inhibitor. Med Lett 1999; 41 (1057): 64–6.Google Scholar
  182. 182.
    Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitorritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277 (1): 423–31.PubMedGoogle Scholar
  183. 183.
    Decker CJ, Laithinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87 (7): 803–7.PubMedCrossRefGoogle Scholar
  184. 184.
    Kaul DR, Cinti SK, Carver PL, et al. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999; 19 (3): 281–98.PubMedCrossRefGoogle Scholar
  185. 185.
    von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38(2): 106–11.Google Scholar
  186. 186.
    Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26 (3): 257–60.PubMedGoogle Scholar
  187. 187.
    Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44 (2): 190–4.PubMedCrossRefGoogle Scholar
  188. 188.
    Chiba M, Hensleigh M, Nishime JA, et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24 (3): 307–14.PubMedGoogle Scholar
  189. 189.
    Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26 (7): 609–16.PubMedGoogle Scholar
  190. 190.
    Barry M, Malcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36 (4): 289–304.PubMedCrossRefGoogle Scholar
  191. 191.
    Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63 (4): 453–64.PubMedCrossRefGoogle Scholar
  192. 192.
    Rana KZ, Dudley MN. Human immunodeficiency virus protease inhibitors. Pharmacotherapy 1999; 19(1): 35–59.PubMedCrossRefGoogle Scholar
  193. 193.
    Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32 (3): 194–209.PubMedCrossRefGoogle Scholar
  194. 194.
    Hsu A, Granneman GR, Bertz R. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35 (4): 275–91.PubMedCrossRefGoogle Scholar
  195. 195.
    Piscitelli S, Flexner C, Minor JR, et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 685–93.PubMedCrossRefGoogle Scholar
  196. 196.
    Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998; 64 (4): 355–62.PubMedCrossRefGoogle Scholar
  197. 197.
    Cato A, Cavanaugh JH, Shi H, et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63 (4): 414–21.PubMedCrossRefGoogle Scholar
  198. 198.
    Kakuda TN, Struble KA, Piscitelli S. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health-Syst Pharm 1998; 55: 233–54.PubMedGoogle Scholar
  199. 199.
    Cheng CL, Smith DE, Carver PL. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997; 61 (5): 531–43.PubMedCrossRefGoogle Scholar
  200. 200.
    Ferry JJ, Herman BD, Carel BJ, et al. Pharmacokinetic drugdrug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (3): 252–9.PubMedCrossRefGoogle Scholar
  201. 201.
    Pharmacia and Upjohn. Rescriptor (delaviradine) package insert. Bridgewater (NJ): Pharmacia and Upjohn, 1998.Google Scholar
  202. 202.
    Murray M, Butler AM. Enhanced inhibition of microsomal cytochrome P340 3A2 in rat liver diltiazem biotransformation. J Pharmacol Exp Ther 1996; 279 (2): 1447–52.PubMedGoogle Scholar
  203. 203.
    Jacolot F, Simon I, Dreano Y, et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991; 41 (12): 1911–9.PubMedCrossRefGoogle Scholar
  204. 204.
    McDonald P, Keough A, Connell J, et al. Diltiazem co-administration reduces cyclosporine toxicity after heart transplantation: a prospective randomized study. Transplant Proc 1992; 24: 2259–62.Google Scholar
  205. 205.
    Campana C, Regazzi MB, Buggia I, et al. Clinically significant drug interactions with cyclosporine: an update. Clin Pharmacokinet 1996; 30: 141–79.PubMedCrossRefGoogle Scholar
  206. 206.
    Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996; 59 (4): 369–75.PubMedCrossRefGoogle Scholar
  207. 207.
    Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64 (4): 369–77.PubMedCrossRefGoogle Scholar
  208. 208.
    Dickenson TH, Egan JM, Abernethy DR. Effects of nifedipine on hepatic drug oxidation. Pharmacology 1988; 36 (6): 405–10.CrossRefGoogle Scholar
  209. 209.
    Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177–82.PubMedCrossRefGoogle Scholar
  210. 210.
    Backman JT, Aranko K, Luurila H, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221–5.PubMedCrossRefGoogle Scholar
  211. 211.
    Grayson HA, Kennedy JD. Torsade de pointes and nifedipine. Ann Intern Med 1982; 97 (1): 144–5.PubMedGoogle Scholar
  212. 212.
    Alderman MH, Cohen H, Roque R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349 (9052): 594–8.PubMedCrossRefGoogle Scholar
  213. 213.
    Prystowsky E. Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 1992; 69: 63D–67D.PubMedCrossRefGoogle Scholar
  214. 214.
    Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2- receptor antagonists. Clin Pharmacol Ther 1999; 65 (4): 369–76.PubMedCrossRefGoogle Scholar
  215. 215.
    Kirch W, Janisch HD, Ohnhaus EE, et al. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 1989; 11 (4): 411–4.PubMedGoogle Scholar
  216. 216.
    Ng PW, Chan WK, Chan TV. Torsade de pointes during the concomitant use of terfenadine and cimetidine. Aust NZ Med 1996; 26(1): 120–1.CrossRefGoogle Scholar
  217. 217.
    Milligan KA, McHugh P. Effects of concomitant administration of cisapride and ranitidine on plasma concentrations in volunteers [abstract]. Br J Anaesth 1989; 63: 628P.Google Scholar
  218. 218.
    Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol 1987; 134 Suppl.: 55–60.CrossRefGoogle Scholar
  219. 219.
    Huber R, Bliesath H, Hartmann M, et al. Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 1998; 36 (10): 521–4.PubMedGoogle Scholar
  220. 220.
    Shinn AF. Clinical relevance of cimetidine drug interactions. Drug Saf 1992; 7: 245–67.PubMedCrossRefGoogle Scholar
  221. 221.
    Steinijans VW, Huber R, Harmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34 (6): 243–62.PubMedGoogle Scholar
  222. 222.
    Curi-Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994; 269 (1): 384–92.PubMedGoogle Scholar
  223. 223.
    Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health-Syst Pharm 1996; 53: 1401–15.PubMedGoogle Scholar
  224. 224.
    Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–41.PubMedGoogle Scholar
  225. 225.
    Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47–58.PubMedGoogle Scholar
  226. 226.
    Spiller HA, Winter ML, Mann KV, et al. Five-year multicenter retrospective review of cyclobenzaprine toxicity. J Emerg Med 1995; 13 (6): 781–5.PubMedCrossRefGoogle Scholar
  227. 227.
    Michalets EL, Smith LK, Van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 1998; 32: 761–4.PubMedCrossRefGoogle Scholar
  228. 228.
    Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79: 983–6.PubMedCrossRefGoogle Scholar
  229. 229.
    Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A4 inhibitors in grapefruit juice. Life Sci 1996; 59: 1025–30.PubMedCrossRefGoogle Scholar
  230. 230.
    Edwards DJ, Bellevue FH, Woster PM. Identification of 6,7-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287–90.PubMedGoogle Scholar
  231. 231.
    Bailey DG, Arnold MO, Strong A, et al. Effect of grapefruit juice naringin on nisoldipine phannacokinetics. Clin Pharmacol Ther 1993; 54: 589–94.PubMedCrossRefGoogle Scholar
  232. 232.
    Bailey DG, Spence JD, Numoz C, et al. Interaction of citrus juice with felodipine and nifedipine. Lancet 1991; 337: 268–9.PubMedCrossRefGoogle Scholar
  233. 233.
    Brunner LJ, Munar MY, Vallian J, et al. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy 1998; 18(1): 23–9.PubMedGoogle Scholar
  234. 234.
    Ameer B, Wintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33 (2): 103–21.PubMedCrossRefGoogle Scholar
  235. 235.
    Kupferschmidt HHT, Ha RH, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20–8.PubMedCrossRefGoogle Scholar
  236. 236.
    Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine phannacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Phannacol Ther 1996; 59: 383–8.CrossRefGoogle Scholar
  237. 237.
    Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Phannacol 1998; 46 (2): 101–10.CrossRefGoogle Scholar
  238. 238.
    Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Phannacol Ther 1997; 61 (4): 395–400.CrossRefGoogle Scholar
  239. 239.
    Gross AS, Goh YD, Addison RS, et al. Influence of grapefruit juice on cisapride phannacokinetics. Clin Pharmacol Ther 1999; 65: 395–401.PubMedCrossRefGoogle Scholar
  240. 240.
    Kivisto KT, Lilja JJ, Backman JT, et al. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66: 448–53.PubMedCrossRefGoogle Scholar
  241. 241.
    Block SH, Carbamazepine-isoniazid interaction. Pediatrics 1982; 69: 494–5.PubMedGoogle Scholar
  242. 242.
    Fleenor ME, Harden JW, Curtis G. Interaction between carbamazepine and antituberculosis agents [letter]. Chest 1991; 99 (6): 1554.PubMedCrossRefGoogle Scholar
  243. 243.
    Ochs HR, Greenblatt DJ, Knuckel M, et al. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol 1983; 16: 743–6.PubMedCrossRefGoogle Scholar
  244. 244.
    Gonzalez A, Sager PT, Akil B, et al. Pentamidine-induced torsade de pointes. Am Heart J 1991; 122: 1489–92.PubMedCrossRefGoogle Scholar
  245. 245.
    Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (torsade de pointes) associated with the use of probucol. New Engl J Med 1991; 326: 1435–6.Google Scholar
  246. 246.
    Bangchang KN, Karbwang J, Back DJ. Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. Biochem Pharmacol 1992; 43 (9): 1957–61.PubMedCrossRefGoogle Scholar
  247. 247.
    Bangchang KN, Karbwang J, Back DJ. Primaquinine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 1992; 44 (3): 587–90.PubMedCrossRefGoogle Scholar
  248. 248.
    Zhao XJ, Yokoyama H, Chiba K, et al. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 1996; 279 (3): 1327–34.PubMedGoogle Scholar
  249. 249.
    Stein LB, Dabezies MA, Silverman M, et al. Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin an nitroglycerin. J Clin Gastroenterol 1992; 15 (2): 171–4.PubMedCrossRefGoogle Scholar
  250. 250.
    Kelly KJ, Stang JM, Mekhjian HS. Vasopressin provocation of ventricular dysrhythmias. Ann Intern Med 1980; 92 (2): 205–7.PubMedGoogle Scholar
  251. 251.
    Minami T, Nishibayashi H, Shinomura Y, et al. Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996; 31: 855–9.PubMedCrossRefGoogle Scholar
  252. 252.
    Hendeles L, Scheife RT, editors. New frontiers in asthma therapy: leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Pharmacotherapy 1997; 17 Suppl.: 1–54S.Google Scholar
  253. 253.
    Loft S, Otton SV, Lennard MS. Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol 1991; 41 (8): 1127–34.PubMedCrossRefGoogle Scholar
  254. 254.
    Brouwers JR. Drug interactions with quinolone antibacterials. Drug Saf 1992; 7 (4): 268–81.PubMedCrossRefGoogle Scholar
  255. 255.
    McLellan RA, Drobitch RK, Monshouwer M, et al. Fluoroquinolones antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996; 24 (10): 1134–8.PubMedGoogle Scholar
  256. 256.
    Yamamoto I, Watanabe K, Marimatsu S, et al. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 1995; 27 (8): 741–6.PubMedCrossRefGoogle Scholar
  257. 257.
    El-Sherif N, Zeiler RH, Carelius W, et al. QTU prolongation and polymorphic ventricular tachycardia due to bradycardia-de-pendent early afterdepolarizations. Circ Res 1988; 63: 286–305.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Internotionol Limited 2000

Authors and Affiliations

  • Elizabeth Landrum Michalets
    • 1
    • 2
    • 3
  • Charlene Rhinehart Williams
    • 1
  1. 1.Department of PharmacyMission + St Joseph’s Health SystemAshevilleUSA
  2. 2.Community Based FacultyUniversity of North Carolina — Chapel Hill School of PharmacyChapel HillUSA
  3. 3.Department of PharmacotherapyMountain Area Health Education CenterAshevilleUSA

Personalised recommendations